ANI Pharmaceuticals, Inc. ( ANIP ) NASDAQ Global Market

Cena: 67.34 ( 0.66% )

Aktualizacja 07-24 17:58
NASDAQ Global Market
Branża: Drug Manufacturers - Specialty & Generic
Statystyki
Dywidendy
Rekomendacje
Wyceny
Wskaźniki
Analiza techniczna

Notowania:

Opis firmy:

Ani Pharmaceuticals, Inc., firma biofarmaceutyczna, opracowuje, produkuje i rynkowe markowe i generyczne farmaceutyki na receptę w Stanach Zjednoczonych i Kanadzie. Koncentruje się na wytwarzaniu kontrolowanych substancji, produktów onkologicznych, hormonów i sterydów, zastrzyków i innych preparatach. Firma produkuje doustne produkty dawki stałych; pół-solidy, płyny i aktualne; oraz silne produkty, a także opracowują rozwój kontraktów i produkcję produktów farmaceutycznych dla innych firm. Wymaga swoich produktów za pośrednictwem łańcuchów farmacji detalicznych, hurtowników, dystrybutorów i apteków wysyłkowych oraz organizacji zakupów grupowych. Firma została zarejestrowana w 2001 roku i ma siedzibę w Baudette w stanie Minnesota.

Informacje o spółce:
Sektor: Zdrowie
Branża: Drug Manufacturers - Specialty & Generic
Zatrudnienie: 642
Giełda: NASDAQ Global Market
Ilość akcji w obrocie: 80.4049
Ilość akcji: Brak danych
Debiut giełdowy: 2000-05-05
WWW: https://www.anipharmaceuticals.com
CEO: Mr. Nikhil Lalwani
Adres: 210 Main Street West
Siedziba: 56623 Baudette
ISIN: US00182C1036
Wskaźniki finansowe
Kapitalizacja (USD) 1 457 985 074
Aktywa: 1 287 377 000
Cena: 67.34
Wskaźnik Altman Z-Score: 1.5
Słaby (wysokie ryzyko bankructwa)
Dywidenda: 0
P/E: -57.1
Ilość akcji w obrocie: 80%
Średni wolumen: 361 121
Ilość akcji 21 651 100
Wskaźniki finansowe
Przychody TTM 555 456 000
Zobowiązania: 856 579 000
Przedział 52 tyg.: 52.5 - 77.0
Piotroski F-Score: 3
Słaby (niska jakość finansowa)
EPS: -1.2
P/E branży: 21.3
Beta: 0.71
Raport okresowy: 2025-08-06
WWW: https://www.anipharmaceuticals.com
Zarząd
Imie i Nazwisko Stanowisko Wynagrodzenie Rok urodzenia
Mr. Ori Gutwerg Senior Vice President of Generics 895 158 1975
Mr. Christopher K. Mutz Senior Vp & Head of Rare Disease 867 919 1972
Mr. Chad Gassert Senior Vice President of Corporate Development & Strategy 849 711 1976
Mr. James G. Marken Senior Vice President of Operations 673 225 1963
Mr. Nikhil Lalwani President, Chief Executive Officer & Director 2 322 211 1978
Mr. Stephen P. Carey Senior Vice President of Finance & Chief Financial Officer 1 110 946 1971
Mr. Muthusamy Shanmugam MS R.Ph. Head of R&D, Chief Operating Officer of Novitium Operations & Director 0 1968
Ms. Elizabeth Powell J.D. Chief Compliance Officer & Head of Legal of Rare Disease 0 0
Ms. Krista L. Davis Senior Vice President & Chief Human Resources Officer 0 1974
Ms. Meredith W. Cook Senior Vice President, General Counsel & Corporate Secretary 0 1975
Lista ETF z ekspozycją na akcje ANI Pharmaceuticals, Inc.
Symbol ETF Ilość akcji Wartość
IJR 1 017 315 66 033 918
IWM 463 155 30 063 398
IWO 160 282 10 403 934
IJT 150 192 9 748 980
SPSM 140 692 9 264 217
PJP 107 621 7 025 498
VTWO 93 343 5 481 100
SLYG 83 964 5 514 573
SCHA 79 354 5 180 229
DFAT 68 202 4 452 226
VIOO 56 122 3 295 483
USVM 55 632 3 631 656
DFAS 55 609 3 630 155
XPH 54 636 3 574 388
VHT 53 955 3 168 237
IHE 47 346 3 073 251
DFAC 44 921 2 932 442
FYX 41 920 2 721 027
FYC 38 687 2 511 173
ITOT 25 562 1 659 221
IDP6.L 24 755 1 606 867
IUS3.DE 24 755 1 606 867
ISP6.L 24 755 1 606 867
VIOG 21 292 1 425 499
AVSC 18 928 1 235 619
PSCH 17 100 1 116 288
DFUV 15 933 1 040 106
EES 15 247 953 852
JPSE 15 119 986 514
WSML.L 14 511 941 925
WLDS.L 14 511 941 925
IUSN.DE 14 511 941 925
BTEE.L 12 816 831 863
2B70.DE 12 816 831 863
BTEC.L 12 816 831 863
BTEK.L 12 816 831 863
PRFZ 12 510 816 652
RWJ 11 801 770 369
VTWG 11 467 673 342
GSSC 10 135 661 612
RSSL 9 910 647 222
ONEQ 7 625 497 760
FHLC 7 337 478 519
RZG 6 921 451 802
BBSC 6 485 423 146
IJR.AX 5 930 590 910
FAD 5 812 377 256
SMLV 5 376 356 041
IWV 5 334 346 245
DFUS 5 037 328 815
SMMV 4 736 309 166
DFAU 3 640 237 619
VTWV 3 566 209 395
XSU.TO 3 263 288 950
PILL 2 291 149 419
ISCV 2 130 138 263
UWM 1 840 120 115
ISCG 1 831 118 874
URTY 1 528 99 747
VTHR 1 507 88 491
DCOR 1 368 89 303
AFSM 1 346 87 368
XJR 1 335 87 148
SPTM 1 098 71 314
TILT 1 086 70 926
CUS1.L 956 62 081
SXRG.DE 956 62 081
CSUSS.MI 956 62 081
CUSS.L 956 62 081
XEQT.TO 943 83 511
IBBQ 891 58 164
ISCB 836 54 247
OMFS 828 54 051
BIB 798 52 093
XUU.TO 793 70 926
XSMC.TO 603 53 425
XSMH.TO 573 50 732
XAW.TO 560 49 562
SAA 309 20 171
AVUS 187 12 207
XBAL.TO 145 13 000
ESIX 128 8 408
XUH.TO 113 7 351
VLU 109 7 100
DXUV 24 1 566
HDG 23 1 501
MMTM 8 519
XTR.TO 5 305
PZW.TO 0 0
USFM.L 0 0
USUE.DE 0 0
Wiadomości dla ANI Pharmaceuticals, Inc.
Tytuł Treść Źródło Aktualizacja Link
ANI Pharmaceuticals to Participate at the H.C. Wainwright 3rd Annual BioConnect Conference at NASDAQ PRINCETON, N.J., May 12, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, and Stephen Carey, Chief Financial Officer, will present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ as follows: globenewswire.com 2025-05-12 22:30:00 Czytaj oryginał (ang.)
ANI (ANIP) is an Incredible Growth Stock: 3 Reasons Why ANI (ANIP) is well positioned to outperform the market, as it exhibits above-average growth in financials. zacks.com 2025-05-12 17:50:46 Czytaj oryginał (ang.)
ANI Pharmaceuticals, Inc. (ANIP) Q1 2025 Earnings Call Transcript ANI Pharmaceuticals, Inc. (NASDAQ:ANIP ) Q1 2025 Earnings Conference Call May 9, 2025 8:00 AM ET Company Participants Lisa Wilson - IR, Insight Communications Nikhil Lalwani - President, CEO & Director Christopher Mutz - SVP, Head, Rare Diseases Stephen Carey - CFO & SVP Conference Call Participants Gary Nachman - Raymond James Faisal Khurshid - Leerink Partners Vamil Divan - Guggenheim Securities David Amsellem - Piper Sandler Ekaterina Knyazkova - J.P. Morgan Les Sulewski - Truist Securities Operator Please stand by. seekingalpha.com 2025-05-09 15:44:46 Czytaj oryginał (ang.)
Is ANI Pharmaceuticals (ANIP) Outperforming Other Medical Stocks This Year? Here is how ANI Pharmaceuticals (ANIP) and Agenus (AGEN) have performed compared to their sector so far this year. zacks.com 2025-05-09 14:46:24 Czytaj oryginał (ang.)
Compared to Estimates, ANI (ANIP) Q1 Earnings: A Look at Key Metrics The headline numbers for ANI (ANIP) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals. zacks.com 2025-05-09 14:30:43 Czytaj oryginał (ang.)
ANI Pharmaceuticals (ANIP) Tops Q1 Earnings and Revenue Estimates ANI Pharmaceuticals (ANIP) came out with quarterly earnings of $1.70 per share, beating the Zacks Consensus Estimate of $1.37 per share. This compares to earnings of $1.21 per share a year ago. zacks.com 2025-05-09 13:10:41 Czytaj oryginał (ang.)
ANI Pharmaceuticals Reports Record First Quarter 2025 Financial Results and Raises 2025 Guidance BAUDETTE, Minn., May 09, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced financial results and business highlights for the first quarter ended March 31, 2025. globenewswire.com 2025-05-09 10:50:00 Czytaj oryginał (ang.)
ANI Pharmaceuticals: A Short-Term Buying Opportunity ANIP is expected to raise 2025 guidance due to FDA approval and launch of TEZRULY and INZIRQO, addressing unmet needs for dysphagic patients. Both drugs are patent protected until 2042 and offer new formulations of established drugs, minimizing launch expenses and maximizing market potential. INZIRQO and TEZRULY could generate significant revenue, with potential annual revenues of $1 billion and $350 million respectively, driving ANIP's PPS higher. seekingalpha.com 2025-05-06 09:43:18 Czytaj oryginał (ang.)
ANI Pharmaceuticals to Report Q1 Earnings: Is a Beat in the Cards? ANIP's first-quarter 2025 revenues are likely to have been driven by increased sales of its lead product, Cortrophin Gel, and other rare disease products. zacks.com 2025-05-05 17:15:33 Czytaj oryginał (ang.)
ANI Pharmaceuticals, Inc. (ANIP) Hit a 52 Week High, Can the Run Continue? ANI (ANIP) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues. zacks.com 2025-05-05 14:15:35 Czytaj oryginał (ang.)
ANI Pharmaceuticals Announces Presentation of Preclinical Data on the Use of Purified Cortrophin® Gel in an Experimental Autoimmune Uveitis (EAU) Mouse Model Demonstrated Dose Dependent Effect in EAU Presented in a podium presentation at The Association for Research in Vision and Ophthalmology (ARVO) 2025 annual meeting PRINCETON, N.J., May 05, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced preclinical data on the use of Purified Cortrophin® Gel (repository corticotropin injection USP) (Cortrophin Gel) in an EAU mouse model. globenewswire.com 2025-05-05 11:00:00 Czytaj oryginał (ang.)
ANI Pharmaceuticals (ANIP) Earnings Expected to Grow: What to Know Ahead of Next Week's Release ANI (ANIP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. zacks.com 2025-05-02 15:06:13 Czytaj oryginał (ang.)
3 Reasons Growth Investors Will Love ANI (ANIP) ANI (ANIP) could produce exceptional returns because of its solid growth attributes. zacks.com 2025-04-25 17:45:35 Czytaj oryginał (ang.)
Are Medical Stocks Lagging ANI Pharmaceuticals (ANIP) This Year? Here is how ANI Pharmaceuticals (ANIP) and Agenus (AGEN) have performed compared to their sector so far this year. zacks.com 2025-04-23 14:46:22 Czytaj oryginał (ang.)
Buy 4 Low-Beta Stocks ANIP, LRN, MASS & CTGO as Tariff Woes Continue It is imperative to build a portfolio of low-beta stocks in a volatile market. ANI Pharmaceuticals, Stride, 908 Devices, & Contango are well-poised to gain. zacks.com 2025-04-23 13:30:40 Czytaj oryginał (ang.)
5 Stocks With Recent Price Strength Amid Tariff-Led Volatility Investors target stocks that are witnessing a bullish run. Some of the stocks seeing price strength are HRTG, MRX, KINS, ANIP, HCI. zacks.com 2025-04-23 11:05:33 Czytaj oryginał (ang.)
4 Stocks Trading Near 52-Week High With Room to Rise Further Investors target stocks that have been on a bullish run lately. Stocks like ANIP, HRTG, AVA and EXC are seeing price strength and the momentum is likely to continue. zacks.com 2025-04-22 13:25:41 Czytaj oryginał (ang.)
ANI Pharmaceuticals, Inc. (ANIP) Soars to 52-Week High, Time to Cash Out? ANI (ANIP) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues. zacks.com 2025-04-17 14:15:38 Czytaj oryginał (ang.)
3 Reasons Why Growth Investors Shouldn't Overlook ANI (ANIP) ANI (ANIP) could produce exceptional returns because of its solid growth attributes. zacks.com 2025-04-09 17:45:37 Czytaj oryginał (ang.)
Will ANI (ANIP) Beat Estimates Again in Its Next Earnings Report? ANI (ANIP) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report. zacks.com 2025-04-09 17:15:53 Czytaj oryginał (ang.)
ANI Pharmaceuticals to Present at Raymond James' Institutional Investors and Leerink Partners Global Healthcare Conferences in March PRINCETON, N.J., Feb. 19, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced that Nikhil Lalwani, President and Chief Executive Officer, and select members of senior management, will present at two upcoming investor conferences as follows: Raymond James & Associates' 46 th Annual Institutional Investors Conference Tuesday, March 4, 2025, at 1:40pm ET Leerink Partners Global Healthcare Conference Tuesday, March 11, 2025, at 3:40pm ET The live and archived webcasts will be accessible from the Company's website at www.anipharmaceuticals.com , under the Investors section under Events and Presentations. globenewswire.com 2025-02-19 18:30:00 Czytaj oryginał (ang.)
ANI Pharmaceuticals to Discuss Fourth Quarter and Full Year 2024 Financial Results on February 28, 2025, at 8:00 a.m. ET PRINCETON, N.J., Feb. 18, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced that the Company will release its fourth quarter and full year 2024 financial results on Friday, February 28, 2025, prior to the market open. globenewswire.com 2025-02-18 18:05:00 Czytaj oryginał (ang.)
Are Investors Undervaluing ANI Pharmaceuticals (ANIP) Right Now? Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. zacks.com 2025-02-17 12:46:15 Czytaj oryginał (ang.)
Are Medical Stocks Lagging ANI Pharmaceuticals (ANIP) This Year? Here is how ANI Pharmaceuticals (ANIP) and Doximity (DOCS) have performed compared to their sector so far this year. zacks.com 2025-02-17 12:41:12 Czytaj oryginał (ang.)
ANI Pharmaceuticals: More Than Just A Generics Company ANI Pharmaceuticals offers an asymmetric opportunity in small-cap pharma, with a niche in generics, rare disease treatments, and contract manufacturing. Despite cash burn concerns, ANI's revenue growth, strategic moves, and overlooked royalty streams indicate long-term value creation. ANI's rare disease asset, Purified Cortrophin Gel, and generics pipeline, including Prucalopride, position it for significant revenue growth and market re-rating. seekingalpha.com 2025-02-11 11:08:03 Czytaj oryginał (ang.)
Is ANI Pharmaceuticals (ANIP) Stock Undervalued Right Now? Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. zacks.com 2025-01-31 12:46:32 Czytaj oryginał (ang.)
Is ANI Pharmaceuticals (ANIP) Stock Outpacing Its Medical Peers This Year? Here is how ANI Pharmaceuticals (ANIP) and CG Oncology, Inc. (CGON) have performed compared to their sector so far this year. zacks.com 2025-01-31 12:40:29 Czytaj oryginał (ang.)
ANI Pharmaceuticals to Present at the Guggenheim Biotech Conference PRINCETON, N.J., Jan. 28, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced that Nikhil Lalwani, President and Chief Executive Officer, and Stephen Carey, Chief Financial Officer, will host a fireside chat at the Guggenheim Biotech Conference in New York City as follows: globenewswire.com 2025-01-28 18:30:00 Czytaj oryginał (ang.)
Is ANI Pharmaceuticals (ANIP) a Great Value Stock Right Now? Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. zacks.com 2025-01-15 12:46:29 Czytaj oryginał (ang.)
Alcami Announces CEO Transition Long time industry leader, Chairman of the Board Patrick Walsh replaces CEO Bill Humphries   DURHAM, N.C. , Jan. 13, 2025 /PRNewswire/ -- Alcami Corporation ("Alcami"), a leading contract development and manufacturing organization (CDMO), today announced the resignation of Bill Humphries. prnewswire.com 2025-01-13 13:12:00 Czytaj oryginał (ang.)
ANI Pharmaceuticals Provides Preliminary Fourth Quarter and 2024 Financial Results and Preliminary 2025 Outlook BAUDETTE, Minn., Jan. 13, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today affirmed its prior net revenues, adjusted non-GAAP EBITDA, and adjusted non-GAAP diluted EPS guidance for 2024 and provided its preliminary financial outlook for 2025. Nikhil Lalwani, ANI's President and Chief Executive Officer, will discuss these updates as part of a presentation at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025, at 2:15 PST/5:15 EST. globenewswire.com 2025-01-13 08:50:00 Czytaj oryginał (ang.)
ANI Pharmaceuticals Announces the FDA Approval and Launch of Prucalopride Tablets with 180-Day CGT Exclusivity PRINCETON, N.J., Jan. 02, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that following final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA), the Company has launched Prucalopride Tablets. ANI's Prucalopride Tablets is the generic version of the reference listed drug (RLD) Motegrity®. globenewswire.com 2025-01-02 08:50:00 Czytaj oryginał (ang.)
Is ANI Pharmaceuticals (ANIP) Outperforming Other Medical Stocks This Year? Here is how ANI Pharmaceuticals (ANIP) and Adaptive Biotechnologies (ADPT) have performed compared to their sector so far this year. zacks.com 2025-01-01 12:51:42 Czytaj oryginał (ang.)
ANI Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference PRINCETON, N.J., Dec. 30, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced that Nikhil Lalwani, President and Chief Executive Officer; Stephen Carey, Chief Financial Officer; and Dr. Mary Pao, Chief Medical Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025, at 2:15pm PST/5:15pm EST, in San Francisco. globenewswire.com 2024-12-30 18:05:00 Czytaj oryginał (ang.)
All You Need to Know About ANI (ANIP) Rating Upgrade to Buy ANI (ANIP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. zacks.com 2024-12-26 15:01:21 Czytaj oryginał (ang.)
Should Value Investors Buy ANI Pharmaceuticals (ANIP) Stock? Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. zacks.com 2024-12-18 12:46:32 Czytaj oryginał (ang.)
Should Value Investors Buy ANI Pharmaceuticals (ANIP) Stock? Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. zacks.com 2024-12-02 17:26:48 Czytaj oryginał (ang.)
ANI Pharmaceuticals to Present at 36th Annual Piper Sandler Healthcare Conference PRINCETON, N.J., Nov. 26, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced that Nikhil Lalwani, President and Chief Executive Officer, and Stephen Carey, Chief Financial Officer, will host a fireside chat at the 36th Annual Piper Sandler Healthcare Conference on Wednesday, December 4, 2024 at 3pm EST in NYC. globenewswire.com 2024-11-26 18:30:00 Czytaj oryginał (ang.)
Does ANI (ANIP) Have the Potential to Rally 31.31% as Wall Street Analysts Expect? The consensus price target hints at a 31.3% upside potential for ANI (ANIP). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. zacks.com 2024-11-26 12:55:16 Czytaj oryginał (ang.)
ANI (ANIP) Upgraded to Buy: What Does It Mean for the Stock? ANI (ANIP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). zacks.com 2024-11-20 15:00:29 Czytaj oryginał (ang.)
Are Investors Undervaluing ANI Pharmaceuticals (ANIP) Right Now? Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. zacks.com 2024-11-14 12:45:50 Czytaj oryginał (ang.)
ANI Pharmaceuticals, Inc. (ANIP) Q3 2024 Earnings Call Transcript ANI Pharmaceuticals, Inc. (NASDAQ:ANIP ) Q3 2024 Earnings Conference Call November 8, 2024 8:00 AM ET Company Participants Lisa Wilson - IR Nikhil Lalwani - President, CEO & Director Christopher Mutz - SVP, Head, Rare Diseases Stephen Carey - CFO & SVP Conference Call Participants David Amsellem - Piper Sandler Gary Nachman - Raymond James Vamil Divan - Guggenheim Securities Operator Good day, everyone, and welcome to today's ANI Pharmaceuticals Inc Third Quarter 2024 Earnings Results Call. Please note that this call is being recorded. seekingalpha.com 2024-11-09 01:05:28 Czytaj oryginał (ang.)
Compared to Estimates, ANI (ANIP) Q3 Earnings: A Look at Key Metrics The headline numbers for ANI (ANIP) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals. zacks.com 2024-11-08 13:02:12 Czytaj oryginał (ang.)
ANI Pharmaceuticals (ANIP) Q3 Earnings and Revenues Surpass Estimates ANI Pharmaceuticals (ANIP) came out with quarterly earnings of $1.34 per share, beating the Zacks Consensus Estimate of $1.09 per share. This compares to earnings of $1.27 per share a year ago. zacks.com 2024-11-08 11:05:16 Czytaj oryginał (ang.)
ANI Pharmaceuticals Reports Record Third Quarter 2024 Financial Results and Raises 2024 Guidance BAUDETTE, Minn., Nov. 08, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced financial results and business highlights for the three months ended September 30, 2024. globenewswire.com 2024-11-08 08:50:00 Czytaj oryginał (ang.)
ANI Pharmaceuticals to Present at Guggenheim's Inaugural Healthcare Innovation Conference and Jefferies London Healthcare Conference in November PRINCETON, N.J., Nov. 04, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced that Nikhil Lalwani, President and Chief Executive Officer, and Stephen Carey, Chief Financial Officer, will present at at two upcoming investor conferences as follows: globenewswire.com 2024-11-04 18:30:00 Czytaj oryginał (ang.)
Earnings Preview: ANI Pharmaceuticals (ANIP) Q3 Earnings Expected to Decline ANI (ANIP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. zacks.com 2024-11-01 13:06:19 Czytaj oryginał (ang.)
ANI Pharmaceuticals to Discuss Third Quarter 2024 Financial Results on November 8, 2024, at 8:00 a.m. ET PRINCETON, N.J., Oct. 30, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced that the Company will release its third quarter 2024 financial results on Friday, November 8, 2024, prior to the market open. globenewswire.com 2024-10-30 19:00:00 Czytaj oryginał (ang.)
ANI Pharmaceuticals Announces the FDA Approval and Launch of Estradiol Gel, 0.06% PRINCETON, N.J., Oct. 25, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that following final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA), the Company launched Estradiol Gel, 0.06%. ANI's Estradiol Gel, 0.06% is the generic version of the reference listed drug (RLD) EstroGel® Gel, 0.06%. globenewswire.com 2024-10-25 10:50:00 Czytaj oryginał (ang.)
ANI Pharmaceuticals to Present New Data Highlighting Membranous Nephropathy Research at American Society of Nephrology Kidney Week 2024 Two poster presentations demonstrate ANI's commitment to research in membranous nephropathy care Two poster presentations demonstrate ANI's commitment to research in membranous nephropathy care globenewswire.com 2024-10-24 10:50:00 Czytaj oryginał (ang.)
Should Value Investors Buy ANI Pharmaceuticals (ANIP) Stock? Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. zacks.com 2024-10-21 14:46:11 Czytaj oryginał (ang.)